OQROGet OQRO Pro
Insider trade

Filana Therapeutics (FLNA)CEO bought ~$414K

Richard Barry, CEO at Filana Therapeutics, bought ~$414K of Filana Therapeutics shares.

~$414K
Approx. value · 150K sh @ $2.76
938K
Holds after · shares reported
Traded
Nov 20, 2025
Filed
Nov 24, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 18, 2025Insider · 1 personInsiders: 2 purchases (~$426K)
  2. Sep 19, 2025Insider · 1 personInsiders: 2 purchases (~$108K)
  3. Sep 22, 2025InsiderCEO purchased ~$16K of FLNA shares in the open market
  4. Oct 21, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors
  5. Oct 21, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member
  6. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
  7. Nov 19, 2025InsiderCEO purchased ~$202K of FLNA shares in the open market
  8. Nov 20, 2025 · this disclosureInsiderCEO purchased ~$414K of FLNA shares in the open market

What came next

  1. Nov 24, 2025Insider · Their first buy on recordDirector purchased ~$25K of FLNA shares in the open market
  2. Dec 12, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On December 12, 2025, the Board of Directors (the “Board”) of Cassava Sciences, Inc. (the “Company”) approved cash bonus awards for calendar 2025 for the Company’s named executive officers in recognition of their contributions to the Company as follows: Name Title Bonus Amount Richard J. Barry President & Chief Executive Officer $ 355,000 Eric J. Schoen Chief Financial Officer $ 215,000 For 2025, the Board…”
  3. Dec 19, 2025Company filing · Form 8-K · Material agreementSigned an important agreement
  4. Mar 10, 2026Company filing · Form 8-K · Bylaws or charter, Reg FDChanged its bylaws, charter or fiscal year, and shared information with investors
  5. Mar 12, 2026Company filing · Form 8-K · ResultsReported its results
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Filana Therapeutics

For Filana Therapeutics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its FLNA page.

Other recent filings by Richard Barry, President & CEO

The full history of Richard Barry, President & CEO is on the profile page.

How this filing works

Other disclosures at Filana Therapeutics

Everything OQRO holds on this company is on its FLNA page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data